Edition:
United Kingdom

Bioblast Pharma Ltd (ORPN.OQ)

ORPN.OQ on NASDAQ Stock Exchange Capital Market

1.12USD
14 Dec 2018
Change (% chg)

$-0.01 (-0.88%)
Prev Close
$1.13
Open
$1.13
Day's High
$1.13
Day's Low
$1.07
Volume
2,258
Avg. Vol
26,593
52-wk High
$5.99
52-wk Low
$1.03

Latest Key Developments (Source: Significant Developments)

Bioblast Pharma Announces Entry Into Merger Agreement To Acquire Enlivex Therapeutics
Monday, 19 Nov 2018 

Nov 19 (Reuters) - Bioblast Pharma Ltd ::BIOBLAST PHARMA LTD. ANNOUNCES ENTRY INTO MERGER AGREEMENT TO ACQUIRE ENLIVEX THERAPEUTICS LTD. TO ADVANCE CLINICAL STAGE IMMUNOTHERAPEUTIC DRUG PIPELINE FOR THE TREATMENT OF LIFE-THREATENING DISEASES SEPSIS, GVHD AND SOLID TUMORS.BIOBLAST PHARMA LTD - TERMS OF TRANSACTION INCLUDE A CONTINGENT VALUE RIGHT (CVR) TO BE DISTRIBUTED TO BIOBLAST SHAREHOLDERS.BIOBLAST PHARMA LTD - OWNERSHIP SPLIT OF COMBINED COMPANY ANTICIPATED TO BE APPROXIMATELY 96% ENLIVEX SHAREHOLDERS AND 4% BIOBLAST SHAREHOLDERS.BIOBLAST PHARMA LTD - COMBINED COMPANY WILL BE RENAMED ENLIVEX THERAPEUTICS LTD., AND ITS TRADING TICKER WILL CHANGE ACCORDINGLY.BIOBLAST PHARMA LTD - "IT IS ANTICIPATED THAT COMBINED COMPANY WILL BE WELL FINANCED AT CLOSING OF TRANSACTION".BIOBLAST PHARMA LTD - EXPECTED THAT SHAI NOVIK, CURRENT EXECUTIVE CHAIRMAN OF ENLIVEX WILL SERVE AS EXECUTIVE CHAIRMAN OF COMBINED COMPANY.BIOBLAST PHARMA LTD - SHMUEL HESS, CURRENT CEO OF ENLIVEX, WILL SERVE AS CEO OF COMBINED COMPANY.  Full Article

Bioblast Pharma Says Effective July 31, Chairman & CEO Will Step Down
Thursday, 26 Jul 2018 

July 26 (Reuters) - Bioblast Pharma Ltd ::BIOBLAST PHARMA - DETERMINED IT IS IN BEST INTEREST OF CO'S SHAREHOLDERS TO FURTHER REDUCE EXPENSES.BIOBLAST PHARMA LTD - EFFECTIVE JULY 31, FREDRIC PRICE WILL BE STEPPING DOWN AS CHAIRMAN & CEO.BIOBLAST PHARMA - FREDRIC PRICE WILL BE LEAVING BOARD, ALONG WITH 4 INDEPENDENT MEMBERS OF BOARD.BIOBLAST PHARMA LTD - WARREN WASIEWSKI, STEPPED DOWN AS COMPANY'S CHIEF MEDICAL OFFICER.BIOBLAST PHARMA LTD - DALIA MEGIDDO, COMPANY CO-FOUNDER, WILL REMAIN ON BOARD AND WILL SERVE AS CEO AND CMO.BIOBLAST PHARMA - WORKING DILIGENTLY TO FIND COMMERCIAL PARTNER FOR INVESTIGATIONAL PROPRIETARY INTRAVENOUS FORM OF TREHALOSE 90 MG/ML SOLUTION.BIOBLAST PHARMA LTD - WORKING DILIGENTLY TO ENTER INTO A MERGER AGREEMENT WITH A THIRD PARTY.  Full Article

Bioblast Pharma reports Q3 loss per share $0.32
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Bioblast Pharma Ltd :Bioblast Pharma reports third quarter 2017 financial results.Q3 loss per share $0.32.  Full Article